Content without topic

Webinar: Update on the impact of nutrition on ASCVD

Philippe Moulin, Jean Michel Lecerf, Ramon Estruch

March 30, 2023 | Webinars on-demand

Webinar: How to get your message through on social media

Jeanine Roeters van Lennep, Kevin Jubbal, Federica Foggaci, Sergio Kaiser

March 15, 2023 | Webinars on-demand

A deep dive into CLEAR OUTCOMES and its implications

Alberico L. Catapano, Lale Tokgözoğlu, Maciej Banach, Steve Nicholls, Ulrich Laufs

March 13, 2023 | Webinars on-demand

EAS Advanced Course – Rare Lipid Disorders – Poland

Maciej Banach, Bozena Sosnowska, Marlena Broncel, Joanna Lewek, Ewa Starostecka, Agata Bielecka-Dabrowa, Matylda Henning, Renata Rajtar-Salwa

March 11, 2023 | Webinars on-demand

Webinar: How to use social media effectively

Jeanine Roeters van Lennep, Sergio Martínez Hervas, Kevin Jubbal, Meral Kayikcioglu, Pierre Sabouret

March 8, 2023 | Webinars on-demand

LCN Lp(a) webinar series #5: Round table with the experts – How to use L(a) in practice, from the point of view of the cardiologist, the lipidologist, the diabetologist and the patient

Alberico L. Catapano, Lale Tokgözoğlu, Kausik Ray, Magdalena Daccord

February 27, 2023 | Webinars on-demand

LCN Lp(a) webinar series #4: Therapeutic approaches – where we stand today and a look to the future

Alberico L. Catapano

January 19, 2023 | Webinars on-demand

LCN Lp(a) webinar series #3: Recommendations for Lp(a) screening

Erik Stroes, Alberico L. Catapano

December 20, 2022 | Webinars on-demand

LCN Lp(a) webinar series #2: Why and how to measure Lp(a)

Florian Kronenberg

November 22, 2022 | Webinars on-demand

Remnant cholesterol: Cardiovascular disease risk, guidelines, and treatment

Borge Nordestgaard

November 17, 2022 |

Cholesterol and triglycerides in ApoB-containing lipoproteins and risk of myocardial infarction

November 17, 2022 |

Metabolism of triglyceride-rich lipoproteins and their remnant lipoproteins in health and dyslipidemiasalth and dys

November 17, 2022 |

Webinar: Beyond targeting LDL cholesterol the role of remnants in cardiovascular disease

Jan Borén, Borge Nordestgaard, Marianne Benn, Mie Balling, Frida Emanuelsson

November 17, 2022 | Webinars on-demand

EAS Advanced Course – Rare Lipid Disorders – Sweden & Norway

Stefano Romeo, Kjetil Retterstøl, Knut Erik Berge, Gisle Langslet, Luca Valenti, Laura Calabresi, Paolo Parini, Emil Andreas Asprusten, Jeanine Roeters van Lennep

November 16, 2022 | Webinars on-demand

Webinar Oct 2022: How to optimize cardiovascular prevention in type 2 diabetic patients at the borders of the guidelines

Philippe Moulin, Ioanna Gouni-Berthold, Bruno Verges

October 27, 2022 | Webinars on-demand

LCN Lp(a) webinar series #1: Lp(a) – what it is, and its role in atherosclerosis

Lale Tokgözoğlu

October 20, 2022 |

EAS Advanced Course – Rare Lipid Disorders – France & Switzerland

Alberico L. Catapano, Mathilde Di-Filippo, Daniel Gaudet, Sophie Beliard, Philippe Moulin, Christel Tran, Noel Peretti, Sybil Charriere, René Valero, Michel Farnier

October 14, 2022 | Webinars on-demand

Hypocholesterolemia friend or foe?

Stefano Romeo, Arca Marcello, Mathilde Di-Filippo, Luca Valenti

September 20, 2022 | Webinars on-demand

How does diabetes accelerate atherosclerosis?

Karin Bornfeldt

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

Macrophage metabolism in atherosclerosis

Laurent Yvan-Charvet

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

Atherosclerosis-associated chronic inflammation: the outcome of metabolic imbalances or irregular immune responses?

Chrysoula Boutari

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

How does endothelial rewiring contribute to ASCVD?

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

Clonal hematopoiesis affecting cardiovascular health

José J. Fuster

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Debate session – HDL: In search for a function – Discussion and Q&A

Giuseppe Danilo Norata, Stefano Romeo, Arnold von Eckardstein, Anne Tybjaerg-Hansen

May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022

HDL: In search for a function – Anne Tybjærg-Hansen

Anne Tybjaerg-Hansen

May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022

HDL: In search for a function – Arnold von Eckardstein

Arnold von Eckardstein

May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022

Aging, dementia and stroke – Discussion and Q&A

Alexandros Tselepis, Ruth Frikke-Schmidt, José J. Fuster, Martin Bennett, Hasanga Manikpurage, Kévin Chemello, Dianne van Dam-Nolen, Olivier Mansier, Liv Nordestgaard

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Body mass index and risk of dementia

Liv Nordestgaard

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Carotid plaque characteristics predict recurrent ischemic stroke: the plaque at risk (parisk) study

Dianne van Dam-Nolen

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Clonal hematopoiesis are not associated with an increased systemic inflammation, atherosclerosis nor incidence of atherothrombosis : results from the 3-city study (chip-3c)

Olivier Mansier

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Combining polygenic risk scores to predict myocardial infarction in the canadian longitudinal study on aging

Hasanga Manikpurage

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Lipoprotein(A) is a residual cardiovascular risk factor in statin treated stroke survivors: insights from the sparcl trial

Kévin Chemello

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Cell senescence in atherosclerosis and vascular ageing

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Imaging guided management – Discussion and Q&A

Ulf Landmesser, Oner Ozdogan, Michael Blaha, Steve Nicholls, Antonio Gallo, Veronika Myasoedova, Horea-Laurentiu Onea, Reindert Oostveen, Paolo Raggi

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Non-alcoholic to metabolic associated fatty liver disease: cardiovascular implications of a change in terminology in patients living with HIV

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Statin treatment dampens arterial wall inflammation assessed with 68GA-dotatate PET/CT

Reindert Oostveen

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

OCT imaging of a wide spectrum of culprit plaque morphology features in acute coronary syndromes

Horea-Laurentiu Onea

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Aortic valve sclerosis in acute myocardial infarction patients and its association with long-term mortality

Veronika Myasoedova

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Non-calcific atherosclerotic burden in hefh: the FH-calc study.

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Imaging for plaque progression

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Imaging guided prevention: Hype or real?

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

New World of targeted therapies (targets, delivery systems,new molecules) – Discussion and Q&A

Franco Bernini, Nathan Wong, Sekar Kathiresan, Megan Levings, Hana Totary-Jain, Alexis Hofherr, Laura D'Erasmo

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Lomitapide in the long-term real-world management of HOFH – effectiveness, tolerability, and hepatic safety data from the pan-european study

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Etesian: a phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Novel anti-atherosclerotic MRNA-based therapy

Hana Totary-Jain

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Cell based therapies in atherosclerosis

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Developing medicines that mimic resistance mutations

Sekar Kathiresan

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Targeting non-coding RNAs

May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies

NLA/EAS joint session – Primordial prevention: The neglected topic – Discussion and Q&A

Joseph Saseen, Kausik Ray, Lale Tokgözoğlu, Kevin Maki, Mai-Lis Hellenius, Anne Carol Goldberg

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

Premordial prevention – How to make it work?

Anne Carol Goldberg

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

Physical activity end cardiovascular prevention

Mai-Lis Hellenius

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

What is the optimal diet to prevent ASCVD?

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

Why do we need primordial prevention?

Lale Tokgözoğlu

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

IME Session – Should public health recommendations target Lp(a) measurements? – Discussion and Q&A

Alberico L. Catapano, Borge Nordestgaard, Elisabeth Steinhagen-Thiessen

May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022

The patient with high Lp(a)

Elisabeth Steinhagen-Thiessen

May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022

Lp(a) a causal risk factor for cardiovascular disease

Borge Nordestgaard

May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022

Understanding 3D culture in smooth muscle cell biology and the modelling of atherosclerosis

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

The epigenetic enzyme DOT1L orchestrates VSMC–monocyte crosstalk to protect against atherosclerosis via the NF-KB pathway

Floriana Farina

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Smooth muscle cell-specific deletion of S100A4 reroutes smooth muscle cell fate and modifies the inflammatory status of murine atherosclerotic lesions

Luis Cardoso dos Santos

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Lamin A/C expression in hematopoietic cells regulates mouse atherosclerosis: a potential mechanism contributing to age-dependent atherosclerosis

Marta Amorós-Pérez

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Gasdermin D deficiency delays atherogenesis but stimulates plaque apoptosis in apoe-/- mice

Pauline Puylaert

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Smooth muscle cells plasticity in plaque stability

Marie-Luce Bochaton-Piallat

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

The role of necroptosis in atherogenesis and plaque stability

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Liver specific targeting of ANGPTL4 using a galnac conjugated antisense oligonucleotides approach

Cholestyramine perinatal treatment of apoe deficient mice reduces atherosclerotic plaques development in adult offspring

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Epigenetics regulate gene expression of metalloprotease-9 and tissue inhibitor of metalloprotease type 2 in acute coronary syndrome

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

A pi3kciialpha/primary cilium-dependent autophagy program protects endothelial cells in response to atheroprone shear stress

Muriel Laffargue

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Silencing of ANGPTL4 via antisense oligonucleotides effectively reduces plasma triglyceride and glucose levels in mice without causing lymphadenopathy

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Antagonism of MIR-148A attenuates the progression of atherosclerosis in apobtgapobec-/-LDLR+/- mice

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Estimating the magnitude of LDL-C reduction needed to overcome the increased risk of atherosclerotic cardiovascular events caused by LP(A) to guide clinical management

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Lipoprotein(A) does not have a clinically significant arterial or venous prothrombotic effect

Elena Olmastroni

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Cell metabolism in endothelial cells

Michael Potente

May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis

Apo B containing lipoproteins – Discussion and Q&A

Arca Marcello, Katariina Öörni, Marina Cuchel, Bart van de Sluis, Willemien van Zwol, Ilenia Minicocci, Manuela Casula, Zivile Girkantaite, Camilla Johannesen

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Importance of APOB and non-HDL cholesterol for ischemic stroke is double that of LDL cholesterol

Camilla Johannesen

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Do triglycerides have an influence on endothelial function detected by laser doppler flowmetry?

Zivile Girkantaite

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

LDL-cholesterol levels and LDL polygenic score in a cohort of patients with clinically diagnosed familial hypercholesterolemia. Data from the lipigen study

May 24, 2022 | FH Week 2022, 90th EAS Congress 2022, Apo B containing lipoproteins

The genetic lack of ANGTPL3 does not alter HDL functionality

Ilenia Minicocci

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Hepatic SMLR1 ablation fully protects against diet-induced atherosclerosis but causes hepatosteatosis via reduced VLDL secretion

Willemien van Zwol

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Intracellular regulation of lipoprotein receptors

Bart van de Sluis

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

LDL disposal: Receptor vs non-receptor

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Lp(a): The next frontier

Sotirios Tsimikas

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

Emerging therapies for dyslipidemia

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

ApoB – friend and foe

Jan Kuivenhoven

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

Trigylcerides: From systemic to cellular metabolism

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

Industrial Breakfast Session – Disussion and Q&A

Michal Vrablik, Matthew Willcox, Ingo Hilgendorf

May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022

Managing LDL-C through a practical lens: A case study

Ingo Hilgendorf

May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022

Managing LDL-C through a behavioral lens – Matthew Willcox

Matthew Willcox

May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022

Managing LDL-C through a clinician’s lens – Michal Vrablík

May 23, 2022 | Industry Breakfast Session, 90th EAS Congress 2022

Industry Special Lecture – Discussion and Q&A

Alberico L. Catapano, Florian Kronenberg, Elisabeth Steinhagen-Thiessen

May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022

Elevated Lp(a) in clinical practice – Implications for managing our patients

Elisabeth Steinhagen-Thiessen

May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022

Why measure Lp(a) and how do I interpret it?

Florian Kronenberg

May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022

Lp(a): What we need to know

Alberico L. Catapano

May 23, 2022 | Industry Special Lecture, 90th EAS Congress 2022

Reductions in VLDL and Remnant Cholesterol through inhibition of ANGPTL3 Protein Synthesis: An Analysis from TRANSLATE-TIMI 70

Nicholas Marston

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Granzyme B+ CD4+ T cells associate with an unstable plaque phenotype in advanced human atherosclerosis

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Identification of CD8+ T cell PRDM1 in high-risk human plaques and its regulatory role in murine lesion development

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Immunumometabolic role of sterol element binding protein 1C (SREBP1C) in tregulatory cell function

Fabrizia Bonacina

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

JMJD3-deficiency in CD4+ T cells attenuates atherosclerosis by modulating T-cell polarization

Cecilia Bonfiglio

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Deletion of viperin in the hematopoietic system aggravates atherosclerosis

Dimitrios Tsiantoulas

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Modulating T cell immunity in ASCVD

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Macrophage plasticity in atherosclerotic plaques

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Why and how to implement early combination lipid lowering therapy – Discussion and Q&A

Maciej Banach, Lale Tokgözoğlu, Carlos Escobar Cervantes, Kausik Ray

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

An App to guide clinical care – what is it and how should we use it

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

How to implement decision algorithms into routine clinical care- experience across Europe

Carlos Escobar Cervantes

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

Pragmatic strategies to better implement combination therapies for very high risk patients

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

How can we optimise lipid lowering after acute coronary syndromes?

Lale Tokgözoğlu

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

Non-classical risk factors: Transitioning from association to causality – Discussion and Q&A

Christoph Binder, Giulia Chiesa, Felix Jansen, Manuel Mayr, Peter Thomas, Florian Mourre, Julia Ramírez, Sabine Bauer, Hyung Joon Joo

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Comparison of cardiovascular prognosis between triglyceride variability and exposure estimate in diabetic patients

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Vascular tissue specific mirna profiles reveal novel correlations with risk factors in coronary artery disease

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Prediction of coronary artery disease and major adverse cardiovascular events using clinical and genetic risk scores for cardiovascular risk factors

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Maternal inheritance of a genetic mutation for familial hypercholesterolemia predispose to coronary atherosclerosis in adulthood

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

High lipoprotein(a) and systemic inflammation jointly confer additive high risk of atherosclerotic cardiovascular disease and aortic valve stenosis

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Systems biology to estimate cardiovascular risk

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Extracellular vesicles in CVD

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

High blood neutrophil counts and ischemic vascular disease: observational and genetic studies

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

High cholesterol absorption is associated with increased cardiovascular risk in hemodialysis patients: insights from the aurora study

Günther Silbernagel

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Effect of genetic susceptibility to common human disorders on plasma lipidome

Rubina Tabassum

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Global perspective of paediatric familial hypercholesterolaemia: analysis from the EAS FHSC registry on over 11,200 children and adolescents with heterozygous familial hypercholesterolaemia from 44 countries

Kanika Dharmayat

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Late breaker session 1

Genome-wide association study on HDL-mediated cholesterol efflux capacity

Johanna Schachtl-Riess

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

A first-in-human single ascending dose study of a monoclonal antibody against the ANGPTL3/8 complex in subjects with mixed hyperlipidemia

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Obicetrapib lowers LDL-C in patients on high intensity statins results from the rose trial (nct04753606)

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

HOFH: new insights in therapeutic approaches – Discussion and Q&A

Philippe Moulin, Frederick Raal, Daniel Gaudet, Arca Marcello

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches

Introduction and case study

May 23, 2022 | 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches

Novel therapeutic options

May 23, 2022 | 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches

HoFH: where do we stand?

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches

Is the risk of atherosclerotic cardiovascular disease different between genotype determined or measured LP(a) levels?

Frederica Galimberti

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Comparison of different LDL-C genetic risk score in a sample of clinical FH patients

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Universal screening is an effective strategy for detecting patients with familial hypercholesterolemia

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK biobank

Jasmine Gratton

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Immune-inflammatory proteomics associated with elevated cardiovascular risk in genetically determined familial hypercholesterolemia

Andrea Baragetti

May 23, 2022 | FH Week 2022, 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Lysosomal acid lipase (LAL) deficiency alters immune cells distribution in mice and humans

Rossella Bellini

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Environment and cardiovascular risk – Discussion and Q&A

Dan Gaita, Jeanine Roeters van Lennep, Patrick Schrauwen, Thomas Münzel, Tess Yntema, David Burgner, Karsten Grote

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Microplastic particles induce endothelial activation

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Early life infection is associated with proinflammatory, atherogenic, and diabetogenic metabolomic and lipidomic profiles at 12 months of age

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Western-type diet overrules the protective effect of commensal bacteria in atherogenesis

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Exercise and cardiovascular disease in 2022: When, who and how ?

Patrick Schrauwen

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Dietary components and patterns as determinants of cardiovascular risk

Alice Lichtenstein

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Lipoprotein(a) and SARS-COV-2 infections: risk for ischemic heart disease and thromboembolic events

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

In vivo detection of urokinase-type plasminogen activator receptor (UPAR) expression in arterial atherogenesis using [64CU]CU-DOTA-AE105 positron emission tomography

Harshvardhan Khare

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

TP53-mutant clonal hematopoiesis accelerates experimental atherosclerosis development

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

Detailing the role of neutrophils in atherothrombosis

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

Platelet activation and inhibition in atherothrombosis and inflammation

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

The human gut microbiome and personalized nutrition

May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle

Carbohydrate/fat or caloric restriction on glycaemia and lipids pathways – what do the trials tell us?

May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle

Can exercise be tailored to address specific risk factors?

Michael Papadakis

May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle

Efficacy of a novel PCSK9 inhibitory peptide alone and in combination with an anti-ANGPTL3 monoclonal antibody in a mouse model of atherosclerosis

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates cholesterol homeostasis and neuroinflammation in cell models of astrocytes and neurons

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

PCSK9 modulates cardiac metabolism and impacts HFPEF

Lorenzo Da Dalt

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

Deciphering PCSK9 function in the intestine

Bertrand Cariou

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

The role of PCSK9 in glucose metabolism and cardiac biology

Giuseppe Danilo Norata

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

IAS/EAS joint session – What is the environment doing to our health? – Discussion and Q&A

Raul Santos, Stefano Romeo, Sanjay Rajagopalan, Thomas Münzel, Khurram Nasir, Ruth Loos

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

Gene environment interaction

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

Social Vulnerability and Cardiovascular Disease

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

Air pollution, City Design and Cardiovascular Disease

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

Heart healthy cities

Sanjay Rajagopalan

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

WHF Session 1: WHF Roadmap on Cholesterol update – Discussion and Q&A

Kausik Ray, Raul Santos, Fernando Lanas Zanetti, Brian Ference

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Cumulative exposure, estimating benefits of early invention of lifetime risk

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Translating science into policy

Fernando Lanas Zanetti

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Implementation today’s key concepts

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Overall Concept

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Stratified treatment of ACS

May 23, 2022 | 90th EAS Congress 2022, Keynote Lecture

Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention – Discussion and Q&A

Alberico L. Catapano, Ian Graham, Brian Ference, Ulrich Laufs, Michal Vrablik

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

How to implement this personalised approach?

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

What is new in secondary prevention?

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

What is new in prevention in apparently healthy persons?

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

Advances in risk estimation

May 23, 2022 | ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

Implementing genetics scores in clinical practice

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Imaging and biomarkers: Targeting the right patient for the right treatment

Wolfgang Koenig

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Vascular response in atherosclerosis: From epigenetics to bone marrow

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Deep phenotyping of disease

Chiara Giannarelli

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Remnant cholesterol, 2022 EAS Anitschkow Lecture

Borge Nordestgaard

The Anitschkow Lecture

Borge Nordestgaard

May 22, 2022 | 90th EAS Congress 2022, Opening Ceremony incl. Anitschkow Lecture

Reimagining population health-the time is now – Discussion and Q&A

Erik Stroes, Marianne Benn, Brian Ference, Lale Tokgözoğlu, Kausik Ray

May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022

Reimagining prevention: the population approach

May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022

Reimagining imaging to guide intensity of treatment – who what and how?

Lale Tokgözoğlu

May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022

Reimagining prevention – Using AI and causal estimates to preserve health?

May 22, 2022 | Reimagining population health-the time is now, 90th EAS Congress 2022

Omega 3 fatty acids in cardiovascular prevention – Where do we stand? – Discussion and Q&A

Alberico L. Catapano, Gabriel Steg, Aldo Pietro Maggioni, Preston Mason

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

Recent trials with Omega 3, lessons to be learned

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

Are omega 3 made all equal?

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

The Omega 3 story from nutrition to pharmacology

Aldo Pietro Maggioni

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

Implementation of the 2019 lipid guidelines-where are we now? – Discussion and Q&A

Alberico L. Catapano, Maurizio Averna, Kausik Ray, Heinz Drexel, Luis Masana, Francois Mach

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Slow and sure wins the race- a stepwise approach

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Start with combination therapy and get on with it

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Using novel therapies in the real world- case studies

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

What’s been achieved and what more is needed – real world evidence

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Diabetes, Obesity and Atherosclerosis – New Horizons in ASCVD Prevention – Discussion and Q&A

Lale Tokgözoğlu, Kausik Ray, Frederick Raal, Mansoor Husain

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

Does targeting incretin pathways impact cardiovascular outcomes

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

Incretin and related pathways and their role in atherosclerosis

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

The epidemiology of DM and obesity and risk of ASCVD

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

Polygenic risk score in the diagnosis of combind hyperlipidemia

Jacqueline Dron

March 17, 2022 | Webinars on-demand

EAS Advanced Course in Rare Lipid Disorders – Polish Lipid Association

Maciej Banach, Marcin Gruchala, Joanna Lewek, Ewa Starostecka, Pawel Burchardt, Malgorzata Mysliwiec, Agnieszka Mickiewicz

March 1, 2022 | Webinars on-demand

EAS Advanced Course, Rare Lipid Disorders in Turkey. Nadir Lipid Bozuklukları -Türkiye

Lale Tokgözoğlu, Meral Kayikcioglu, Oner Ozdogan, Bugra Ozkan, Ozcan Basaran, Yagiz Uresin, Baris Gungor, Murat Akova

January 7, 2022 | Webinars on-demand

Prevention and Treatment of Atherosclerosis – Improving State-of-the-Art Management and Search for Novel Targets

January 1, 2022 | Publications, Handbook

How infraclinic atherosclerosis assessment contributes to personalized lipidology

Eric Bruckert, Stephan Gielen, Sara Boccalini, Philippe Moulin

Webinars on-demand

EAS Advanced Course in Rare Lipid Disorders – from Vienna

Christoph Binder, Arnold von Eckardstein, Yvonne Winhofer-Stockl, Florian Kronenberg, Thomas Stulnig, Thorsten Hornemann, Albina Nowak

November 26, 2021 | Webinars on-demand

Aligning plasma lipidomics and metabolic studies in lipid metabolism

Jan Borén, Peter Würtz, Gerald Watts, Marianne Benn

Webinars on-demand

Open Lecture Nov 2021: Gene-based therapies – The next generation of Atherosclerosis treatment

Rosanne M. Crooke, Kees Hovingh

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

November 8, 2021 | Consensus paper, Publications

EAS Advanced Course – Rare Lipid Disorders – from Lisbon

Alberico L. Catapano, Francisco Araujo, Paula Freitas, Mafalda Bourbon, Sequeira Duarte, Borge Nordestgaard, Shailesh Patel

November 6, 2021 | Webinars on-demand

From genomics to gene expression in cardiovascular disease

Kári Stefánsson, Minna Kaikkonen-Määttä, Ruth Loos, Christoph Binder

Webinars on-demand

Women, dyslipidaemia and atherosclerosis

Lale Tokgözoğlu, Fabrice Bonnet, Erin D. Michos, Jeanine Roeters van Lennep

Webinars on-demand

Fatty Liver and Cardiovascular Disease: Partners in Crime?

Christopher D Byrne, Stefano Romeo, Luca Valenti, Olov Wiklund

Webinars on-demand

Lipids and atherosclerosis in COVID era

Giuseppina Caligiuri, Alberto Corsini, Handrean Soran, Lale Tokgözoğlu

Webinars on-demand

Understanding lipoprotein(a) in cardiovascular disease

Pia Rørbæk Kamstrup, Alexandros Tselepis, Massimiliano Ruscica, Stefano Romeo

October 27, 2021 | Webinars on-demand

EAS Advanced Course in Rare Lipid Disorders – from Copenhagen

Ruth Frikke-Schmidt, Jan Borén, Anne Tybjaerg-Hansen, Borge Nordestgaard, Knut Erik Berge, Laura Calabresi, Dagmar Kratky, Robert Hegele, Stephen Young

October 8, 2021 | Webinars on-demand

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

September 30, 2021 | Guideline, Publications

Weight reduction and atherosclerotic benefits ; from actual evidence to future challenges

89th EAS Congress 2021

Impaired resolution of inflammation – role of lipid mediators

89th EAS Congress 2021

Humoral immune responses in the artery wall.

Christoph Binder

89th EAS Congress 2021

How to optimize CVD risk reduction

Francesco Cosentino

89th EAS Congress 2021

How to optimize atherothromobotic therapies to reduce CVD risk

89th EAS Congress 2021

HoFH – can we move away from apheresis

FH Week 2022, 89th EAS Congress 2021

Gender and Cardiovascular Disease

DeLisa Fairweather

89th EAS Congress 2021

Gender specific risks in women

Jeanine Roeters van Lennep

89th EAS Congress 2021

From risk factors to acute coronary syndrome in women

Lale Tokgözoğlu

89th EAS Congress 2021

Fibrates to date – a bridge too far

89th EAS Congress 2021

Exercise inactivity and circadian rhythms – re-setting the clock in metabolic disease

89th EAS Congress 2021

Evolving Concepts- Moving from PPAR to SPARM

89th EAS Congress 2021

Dietary polyphenols and arterial stiffness

89th EAS Congress 2021

Coronary Artery Calcification and its Progression: What Does it Really Mean?

89th EAS Congress 2021

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

September 7, 2021 | Publications

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

September 2, 2021 | Consensus paper, Publications

The new guidelines for dyslipidaemia

Intro to Clinical Lipidology

The clinical experience

Intro to Clinical Lipidology

Ongoing studies

Intro to Clinical Lipidology

Mendelian randomization

Intro to Clinical Lipidology

CV disease risk classification

Lale Tokgözoğlu

Intro to Clinical Lipidology

Current available therapies – Statins

Intro to Clinical Lipidology

Current available therapies – PCSK9 inhibition

Intro to Clinical Lipidology

Current available therapies – Omega3 & fibrates

Intro to Clinical Lipidology

Current available therapies – Ezetimbe

Alberico L. Catapano

Intro to Clinical Lipidology

Course presentations – An Introduction to Clinical Lipidology, October 2019

Lale Tokgözoğlu

Intro to Clinical Lipidology

Bempedoic acid – Mechanism of action

Alberico L. Catapano

Intro to Clinical Lipidology

The role of Dendritic Cells in Atherosclerosis

Clement Cochain

T cell subsets in atherosclerosis

Ontogeny and atherosclerosis pathology of B lymphocytes

Immunomodulation of atherosclerosis

Daniel F.J. Ketelhuth

Exploration and modulation of regulatory T cells in atherosclerosis

Hafid Ait-Oufella

Emerging cardiovascular therapies targeting the immune system

Circulating Cells and Cardiovascular Risk

Harry Björkbacka

The role of new lipid lowering drugs

The population burden of FH- The need to close the gap

The lipid clinic and organization of FH, the role of different participants in the team

Kjetil Retterstøl

Swedish experience from patient society

Gunnar Karlsson

Genetics of FH mutation and distribution

Diagnosis of FH – Scoring systems and Genetic diagnosis, Polygenic causes of clinical FH

Cascade screening introduction and experience from Spain

Cascade screening introduction and experience from Czech Republic

Tomas Freiberger

What have Mendelian Randomization studies revealed for cardiovascular disease beyond lipids?

EAS AC on Epidemiology & Genetics

Using genetics to predict drug effects and adverse events

Anne Tybjaerg-Hansen

EAS AC on Epidemiology & Genetics

The case of lipoprotein(a) and cardiovascular disease

Pia Rørbæk Kamstrup

EAS AC on Epidemiology & Genetics

The case for triglyceride-rich lipoproteins and cardiovascular disease

Borge Nordestgaard

EAS AC on Epidemiology & Genetics

New and old lipid-lowering drugs

Lale Tokgözoğlu

EAS AC on Epidemiology & Genetics

Global burden of cardiovascular disease and contribution of risk factors

EAS AC on Epidemiology & Genetics

Genetic disorders of lipid metabolism – with special focus on familial hypercholesterolaemia

EAS AC on Epidemiology & Genetics

Concepts of Mendelian randomization

EAS AC on Epidemiology & Genetics

Causality of lipid traits for other diseases

Ruth Frikke-Schmidt

EAS AC on Epidemiology & Genetics

Biology of lipid metabolism

EAS AC on Epidemiology & Genetics

2016 ESC-EAS guidelines for the management of dyslipidaemias-risk prediction and treatments targets

EAS AC on Epidemiology & Genetics

Regulation of lipid metabolism by inflammation

Laurent Yvan-Charvet

EAS AC on Dyslipidaemia & Inflammation

EAS AC on Dyslipidaemia & Inflammation

Innate immunity – Inflammasome

EAS AC on Dyslipidaemia & Inflammation

Adaptive Immunity – T cells and B cells

EAS AC on Dyslipidaemia & Inflammation

Plasma lipoproteins and their role in atherogenesis

EAS AC in Lipidology

PCSK9 inhibitor therapy – The cure for atherosclerosis?

EAS AC in Lipidology

PCSK9 Inhibition – HIGHLIGHTS FROM RECENT PUBLICATIONS

Alberico L. Catapano

EAS AC in Lipidology

PCSK9 – From promise to clinical practice

EAS AC in Lipidology

Panel discussion

Faculty Presenter(s)

EAS AC in Lipidology

Lipid lowering therapies – statins

EAS AC in Lipidology

Lipid guidelines, where we stand?

Alberico L. Catapano

EAS AC in Lipidology

Introduction to the course

Alberico L. Catapano

EAS AC in Lipidology

HDL, non HDL cholesterol and TG – a role in atherosclerosis?

EAS AC in Lipidology

Genetics for the identification of therapeutic targets in dyslipidaemia

EAS AC in Lipidology

Familial hypercholesterolemia detection and treatment and the EAS Initiatives

EAS AC in Lipidology

Epidemiology of dyslipidemias focus on the region

EAS AC in Lipidology

CVD – Epidemiology of the risk factors – the central role of LDL cholesterol

Lale Tokgözoğlu

EAS AC in Lipidology

Combination Therapy with non-Statin lipid lowering therapies

EAS AC in Lipidology

Closing remarks

Alberico L. Catapano

EAS AC in Lipidology

Clinical Cases Discussion

Faculty Presenter(s)

EAS AC in Lipidology

Will precision medicine help tailor dyslipidemia treatment?

EAS 2017 AC on Precision Medicine in A

Precision Cardiovascular Medicine – an unmet need or just a fashion?

Eran Leitersdorf

EAS 2017 AC on Precision Medicine in A

Nutrigenomics for prevention and treatment of obesity

Judith Aron-Wisnewsky

EAS 2017 AC on Precision Medicine in A

Is there a role for Advanced Atherosclerosis Imaging in targeted cardiovascular therapy?

EAS 2017 AC on Precision Medicine in A

Identification of novel targets in Hypertension and priorities for drug development

David Rosenbaum

EAS 2017 AC on Precision Medicine in A

Human Genetics from validation of novel cardiovascular drug targets to molecular diagnosis

EAS 2017 AC on Precision Medicine in A

Do Novel Biomarkers improve cardiovascular risk stratification?

Arnold von Eckardstein

EAS 2017 AC on Precision Medicine in A

Can we refine strategy on HDL by new pharmacological approaches?

EAS 2017 AC on Precision Medicine in A

Venous vs. arterial thrombosis

EAS 2017 AC on Atherothrombosis

EAS 2017 AC on Atherothrombosis

Systemsbiology and cardiovascular disease

EAS 2017 AC on Atherothrombosis

Platelets and the vascular wall

EAS 2017 AC on Atherothrombosis

Monocytes and atherothrombosis

EAS 2017 AC on Atherothrombosis

Mechanisms of plaque rupture and erosion

Gerard Pasterkamp

EAS 2017 AC on Atherothrombosis

Immunothrombosis

Steffen Massberg

EAS 2017 AC on Atherothrombosis

Humoral immunity and thrombosis

Christoph Binder

EAS 2017 AC on Atherothrombosis

Gut microbiome and atherothrombosis

Christoph Reinhardt

EAS 2017 AC on Atherothrombosis

Clotting factors and atherothrombosis

EAS 2017 AC on Atherothrombosis

Clinical aspects of atherothrombosis

EAS 2017 AC on Atherothrombosis

Antiphospholipid antibodies and thrombosis

EAS 2017 AC on Atherothrombosis

Recent evidence for the prevention of atherosclerotic cardiovascular diseases

Basic science perspectives

Lipoprotein Metabolism

Arnold von Eckardstein

Basic science perspectives

Treatment of FH – Diet, statin and statin intolerance

An introduction to FH for clinicians

An introduction to FH for clinicians

An introduction to Familial Hypercholesterolaemia for clinicians

An introduction to FH for clinicians

Training Agenda Overview

Alberico L. Catapano

An Introduction to Clinical Lipidology

The new guidelines for dyslipidaemia

Alberico L. Catapano

An Introduction to Clinical Lipidology

Statins, including intolerance

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

PCSK9 Inhibition including Inclisiran

An Introduction to Clinical Lipidology

Omega 3 and fibrates

An Introduction to Clinical Lipidology

Management of dyslipidaemic patients in clinical practice

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

Lipoprotein metabolism and the causal role of LDL in atherosclerosis

An Introduction to Clinical Lipidology

Guidelines – the goals why?

Alberico L. Catapano

An Introduction to Clinical Lipidology

Guidelines – FH patients

An Introduction to Clinical Lipidology

Guidelines – Diabetic patients

An Introduction to Clinical Lipidology

Guidelines – Diabetic patients

An Introduction to Clinical Lipidology

Guidelines – ACS & very highrisk patients

An Introduction to Clinical Lipidology

Guidelines – ACS & very high risk patients

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

An Introduction to Clinical Lipidology

EAS Introduction

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

CV disease risk classification

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

Bempedoic Acid – The clinical experience

An Introduction to Clinical Lipidology

Bempedoic Acid – Mechanism of action

Alberico L. Catapano

An Introduction to Clinical Lipidology

What is the landscape on lipid management today?

Lale Tokgözoğlu

88th EAS Congress 2020

What is the environment doing to cardiovascular health?

Nicole Probst-Hensch

88th EAS Congress 2020

What do we know so far about bempedoic acid?

88th EAS Congress 2020

Translating science into guidance on the prevention of cardiovascular disease

88th EAS Congress 2020

The value of omega 3 – from biology to clinical practice

88th EAS Congress 2020

The lipoprotein(a) story – from risk factor to causality to clinical trials

Sotirios Tsimikas

88th EAS Congress 2020

The biology of PCSK9

Bertrand Cariou

88th EAS Congress 2020

The Angiopoietin-like proteins, controlling lipoprotein metabolism

88th EAS Congress 2020

TG-rich lipoproteins as a risk factor

Ruth Frikke-Schmidt

88th EAS Congress 2020

siRNA based approaches targeting hepatic synthesis of PCSK9

88th EAS Congress 2020

Risk stratification in very high risk patients is it of value?

Faculty Presenter(s)

88th EAS Congress 2020

Prevention of cardiovascular diseases by glucose lowering drugs

Stefano Del Prato

88th EAS Congress 2020

Position of omega 3 in Guidelines (as second choice after statins)

Christie Ballantyne

88th EAS Congress 2020

New therapeutic approaches

John J. Kastelein

88th EAS Congress 2020

Monoclonal antibody approaches targeting circulating PCSK9

88th EAS Congress 2020

Implementing systems biology to personalise medicine

Johan Björkegren

88th EAS Congress 2020

Immune modulation in atherosclerosis

88th EAS Congress 2020

Global perspectives of cardiovascular disease, and impact of risk factors

88th EAS Congress 2020

Difficult cases to reach goal – Recurrent event on statin

88th EAS Congress 2020

Difficult cases to reach goal – FH

Meral Kayikcioglu

88th EAS Congress 2020

Case – Diabetic patient with MI – how to manage?

Dirk Muller-Wieland

88th EAS Congress 2020

Can polygenic scores reach clinical practice?

Anne Tybjaerg-Hansen

88th EAS Congress 2020

Can combination aid adherence ? (fixed dose, intolerance)

88th EAS Congress 2020

Are the new EAS-ESC lipids goals reachable in clinical practice?

88th EAS Congress 2020

Anitschkow Lecture – The Oxidation Hypothesis of Atherosclerosis Revisited – A Pivotal Role of OxPL in Atherosclerosis, NASH and Inflammation

Joseph L. Witztum

88th EAS Congress 2020

An update on the results of ODYSSEY outcomes

88th EAS Congress 2020

AI in CVD & beyond

88th EAS Congress 2020

Behaviour change in CVD prevention

88th EAS Congress 2020

Precision nutrition and CVD management

88th EAS Congress 2020

What is the price to pay if we are not at goal?

87th EAS Congress 2019

What is the evidence for upfront combination?

87th EAS Congress 2019

The metabolic basis of FCS

87th EAS Congress 2019

The immune system – The next game-changer?

Matthias Nahrendorf

87th EAS Congress 2019

The HDL story – Time to reconsider?

87th EAS Congress 2019

The genetic evidence for inhibiting the cholesterol synthesis pathway to control LDL cholesterol

87th EAS Congress 2019

The genetic burden in CVD

Heribert Schunkert

87th EAS Congress 2019

The criticality of LDL goal attainment

87th EAS Congress 2019

System-Level analyses of inflammatory and repair Macrophages reveal an integrated circuitry of lipid and epigenomic changes

87th EAS Congress 2019

Risk Prediction for Add on Lipid Modulating Therapy

87th EAS Congress 2019

Reduce-It – An in depth analysis

Christie Ballantyne

87th EAS Congress 2019

Reality check – Can we get to Guideline recommended targets?

Kornelia Kotseva

87th EAS Congress 2019

Possibilities for Nutrigenetics and Nutraceuticals in CVD prevention

87th EAS Congress 2019

Physician-Patient relationship – Challenges and opportunities

Lale Tokgözoğlu

87th EAS Congress 2019

Pharmacology of Bempedoic acid

Giuseppe Danilo Norata

87th EAS Congress 2019

PCSK9 inhibition in clinical practice

87th EAS Congress 2019

Optimising cholesterol lowering treatment – How many times do we learn the same lesson?

87th EAS Congress 2019

Optimal lipid lowering therapy – New and established therapies

Christie Ballantyne

87th EAS Congress 2019

Omega 3 fatty acids – Biological functions

Alexandros Tselepis

87th EAS Congress 2019

Omega 3 and CV benefit a review of the clinical trials

Aldo Pietro Maggioni

87th EAS Congress 2019

New lipid drugs – Is LDL done, ready for new targets?

87th EAS Congress 2019

Modified lipids and lipoproteins

Joseph L. Witztum

87th EAS Congress 2019

Microbiome – A New Theory of Atherosclerosis?

87th EAS Congress 2019

Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis

87th EAS Congress 2019

Inflammation, Inhibition and Atherothrombosis

87th EAS Congress 2019

How good are we in reaching the goals?

87th EAS Congress 2019

Estimating risk – What’s new?

87th EAS Congress 2019

Efficacy and safety of nutraceuticals

87th EAS Congress 2019

Different approaches to LDL lowering – An overview of options including nutrition, food supplements, and drug therapy

87th EAS Congress 2019

Current evidence for LDL causality; Goals and targets

87th EAS Congress 2019

Complex cases in lipid lowering treatment – One simple high intensity cholesterol lowering approach fits them all

Arman Postadzhiyan

87th EAS Congress 2019

Clinical experience with Bempedoic Acid

Christie Ballantyne

87th EAS Congress 2019

Cardiovascular aging and Mitochondia function

87th EAS Congress 2019

Biomarkers predicting CVD

87th EAS Congress 2019

A Journey From Plaque to Pate

87th EAS Congress 2019

A deep look to the results of Odyssey outcomes

J. Wouter Jukema

87th EAS Congress 2019

Will inhibiting thrombus formation prevent acute coronary syndromes?

86th EAS Congress 2018

Will aggressive LDL reduction prevent atherosclerosis?

Alberico L. Catapano

86th EAS Congress 2018

Why does the diet rich in unsaturated fat protect against cardiovascular disease? Differences between nuts and extra virgin olive oil

86th EAS Congress 2018

The role of bile acids in cholesterol homeostasis

Albert K. Groen

86th EAS Congress 2018

The multifaceted aspects of CV prevention – from nutrition to therapy – Chair

Alberico L. Catapano, Alberto Mello e Silva, Xavier Pinto

86th EAS Congress 2018

The ideal patient for PCSK9

J. Wouter Jukema

86th EAS Congress 2018

The Anitschkow Lecture – Genetics of cardiovascular disease – from ugly duckling to beautiful swan

Anne Tybjaerg-Hansen

86th EAS Congress 2018

Stress, behavior and cardiovascular disease

Viola Vaccarino

86th EAS Congress 2018

Strategies to treat vulnerable plaques

86th EAS Congress 2018

Silencing genes, new targets

Sotirios Tsimikas

86th EAS Congress 2018

Shifting concepts in the description of the vulnerable plaque

Gerard Pasterkamp

86th EAS Congress 2018

Science versus reality in long term management – Time for a paradigm shift?

Lale Tokgözoğlu

86th EAS Congress 2018

RNA editing controls atherosclerosis

Stephanie Dimmeler

86th EAS Congress 2018

Reducing cholesterol by dietary means

86th EAS Congress 2018

Reality check – Can we get to goals in guidelines?

86th EAS Congress 2018

PCSK9 inhibition the clinical evidence

86th EAS Congress 2018

PCSK9 Inhibition in high risk patients

86th EAS Congress 2018

Patient journey after acute coronary syndromes – can we improve outcomes? – Chair

86th EAS Congress 2018

Panel Discussion

Faculty Presenter(s)

86th EAS Congress 2018

Optimising therapy through cardiac rehabilitation

86th EAS Congress 2018

Novel therapeutic approaches using antisense inhibition

Joseph L. Witztum

86th EAS Congress 2018

Novel role of a Triglyceride-synthesizing enzyme – DGAT1 at the crossroad between Triglyceride and cholesterol metabolism

86th EAS Congress 2018

New targets for controlling dyslipidaemias and atherosclerosis – chair

86th EAS Congress 2018

Neoatherosclerosis from a pathologist’s point of view

86th EAS Congress 2018

Nanomedicine as novel atherosclerosis therapy

Willem J.M Mulder

86th EAS Congress 2018

Molecular and biochemical mechanisms involved in the protective effect of Mediterranean diet against atherosclerosis

86th EAS Congress 2018

Mining the blood for new cardiometabolic markers

Robert Gerszten

86th EAS Congress 2018

Lipids, inflammation and CV risk

86th EAS Congress 2018

Lipid Signaling pathways in physiology and disease

86th EAS Congress 2018

Lessons from genetics – risk-score and novel candidates

86th EAS Congress 2018

Lessons from epidemiology and environmental CVD risk factors

86th EAS Congress 2018

LDL and apoB-lipoprotein as causative agents in ASCVD

86th EAS Congress 2018

Keynote Lecture – Chair

86th EAS Congress 2018

Is there need to revise goals from lipid lowering?

86th EAS Congress 2018

Incremental value of established therapies for dyslipidaemic patients

86th EAS Congress 2018

Imaging and CVD risk estimation (population studies)

Valentin Fuster

86th EAS Congress 2018

How to control atherogenic dyslipidaemia

86th EAS Congress 2018

Hospital management after acute coronary syndromes – Is the risk over ?

Jose L Zamorano

86th EAS Congress 2018

High-resolution lipoprotein phenotypes and cardiovascular outcomes

86th EAS Congress 2018

Genetic regulation of HDL cholesterol levels during sepsis

86th EAS Congress 2018

Genes can hurt you to develop CVD beyond classical risk factors

86th EAS Congress 2018

Food4me – the experience

86th EAS Congress 2018

Effects of the different dietary fatty acids on health – focus on PUFA n-6. New evidences and controversies

86th EAS Congress 2018

Dysregulation of hepatic and lipoprotein metabolism in the atherogenic dyslipidemia

Marja-Riitta Taskinen

86th EAS Congress 2018

Dietary fat vs carbohydrates

Gabriele Riccardi

86th EAS Congress 2018

Diet and CVD the epidemiological view

86th EAS Congress 2018

Development of antisense drug targeting PCSK9

Mariko Harada-Shiba

86th EAS Congress 2018

Defective Inflammation Resolution in Atherosclerosis – Mechanisms and Therapeutic Opportunities

86th EAS Congress 2018

Combination therapy – When and how

86th EAS Congress 2018

Atherothrombosis; from pathogenesis to treatment

Steffen Massberg

86th EAS Congress 2018

Are we ready to test the Lp(a) Hypothesis?

Sotirios Tsimikas

86th EAS Congress 2018

Apo B containing lipoproteins a better target for CV risk reduction?

86th EAS Congress 2018

Anti-Inflammatory Therapy for Atherosclerosis – Theory and Practice

86th EAS Congress 2018

A plasma circulating MIRNAS profile predicts Type 2 Diabetes MELLITUS and Prediabetes – From the cordioprev study

Antonio Camargo

86th EAS Congress 2018

A contemporary approach to dyslipidaemias, PCSK9 inhibition

86th EAS Congress 2018

Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? – Introduction

85th EAS Congress 2017

Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

Using naturally randomized genetic evidence to understand heritability of coronary artery disease?

85th EAS Congress 2017

Updates on the guidelines. Which role for nutraceuticals?

85th EAS Congress 2017

Typical clinical cases – who may benefit?

85th EAS Congress 2017

The value of generic medicines

85th EAS Congress 2017

The new EAS-ESC Guidelines on diet and lifestyle in cardiovascular prevention

Gabriele Riccardi

85th EAS Congress 2017

The clinical evidence – Meta-analysis of the RCT

85th EAS Congress 2017

The case for immune cells – An expanded cardiovascular continuum

85th EAS Congress 2017

Temporal versus one-time biomarker measurements

85th EAS Congress 2017

Summary and introduction of guidelines

Alberico L. Catapano

85th EAS Congress 2017

Secondary prevention

85th EAS Congress 2017

Role of non-coding RNA for cholesterol homeostasis and atherogenesis

85th EAS Congress 2017

Regulation of lipid mobilization and lipoprotein secretion by the intestine

85th EAS Congress 2017

Progress in understanding the role of nutrition in prevention of atherosclerosis – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

Progress in understanding the role of nutrition in prevention of atherosclerosis – Chair

85th EAS Congress 2017

Prognostics in patients with manifest (acute or chronic) CHD

85th EAS Congress 2017

Primary prevention

85th EAS Congress 2017

85th EAS Congress 2017

Nordic and Mediterranean diet patterns from the CVD point of view

85th EAS Congress 2017

Microbiome and cardiometabolic disease

Fredrik Bäckhed

85th EAS Congress 2017

Mechanistic insights into innovative therapeutics in lipid lowering in vivo

85th EAS Congress 2017

Lysosomal acid lipase deficiency – an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction

Maurizio Averna

85th EAS Congress 2017

Lowering LDL-C for cardiovascular disease

85th EAS Congress 2017

Life time exposure to LDL-cholesterol is it the key to CVD risk?

85th EAS Congress 2017

LDL is causal to atherosclerosis

85th EAS Congress 2017

Large-scale epidemiology assessment of the main determinants of cardiovascular disease

Sarah Lewington

85th EAS Congress 2017

LAL deficiency – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

Introduction to Detecting plaque burden or vulnerable plaque – Which way should we go?

Lale Tokgözoğlu

85th EAS Congress 2017

Introduction to Anitschkow prize winner

Lale Tokgözoğlu

85th EAS Congress 2017

Innate immune response drives atherosclerosis

85th EAS Congress 2017

Importance of physical activity in metabolic and cardiovascular health and the influence of obesity and diabetes

Patrick Schrauwen

85th EAS Congress 2017

Hypertriglyceridaemia – ApoC-III and ANGPTL3

Sotirios Tsimikas

85th EAS Congress 2017

How to treat diabetic dyslipidaemia – Introduction

Borge Nordestgaard

85th EAS Congress 2017

How to treat diabetic dyslipidaemia

85th EAS Congress 2017

How to treat diabetic dyslipidaemia

85th EAS Congress 2017

How LDL causes inflammation in the artery wall

85th EAS Congress 2017

Hepatic lipid and lipoprotein metabolism

Marja-Riitta Taskinen

85th EAS Congress 2017

HDL-cholesterol and cardiovascular disease – rethinking our approach

85th EAS Congress 2017

FOURIER – first outcomes data with a PCSK9 inhibitor

Terje R Pedersen

85th EAS Congress 2017

Fibrates in the management of AD and CVD risk

85th EAS Congress 2017

Familial hypercholesterolaemia

85th EAS Congress 2017

Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency

85th EAS Congress 2017

Discussion – What do FOURIER data mean for clinical practice?

Faculty Presenter(s)

85th EAS Congress 2017

Diet and cardiometabolic health

85th EAS Congress 2017

Demystifying the management of hypertriglyceridemia

Anne Tybjaerg-Hansen

85th EAS Congress 2017

CVD prevention strategies – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

85th EAS Congress 2017

Combination therapy a better way to treat?

Lale Tokgözoğlu

85th EAS Congress 2017

Circulating miRNA for cardiovascular death prediction

85th EAS Congress 2017

Circadian control of metabolism

Frank A.J.L. Scheer

85th EAS Congress 2017

Chronic kidney disease

Alexandros Tselepis

85th EAS Congress 2017

Brown adipose tissue – a novel target to comBAT cardiometabolic disease

85th EAS Congress 2017

Balancing the fat – lipid droplets and human disease

Robert Farese, Jr

85th EAS Congress 2017

Atherosclerosis regression – linking GLAGOV and FOURIER

85th EAS Congress 2017

Atherogenic dyslipidemia (AD)

85th EAS Congress 2017

Anitschkow Lecture – Hematopoiesis, cholesterol and atherosclerosis

85th EAS Congress 2017

85th EAS Congress 2017

How genes control cholesterol

Michael S Brown

84th EAS Congress 2016

Anitschkow Lecture

John J. Kastelein

82nd EAS Congress 2014

The Anitschkow lecture

81st EAS Congress 2013

A brief history of cholesterol lowering

Terje R Pedersen

Overview of the role of lipids in atherosclerosis

2019 Intro to Clinical Lipidology

Genetic disorders of lipid metabolism with special focus on familial hypercholesterolaemia

2019 Intro to Clinical Lipidology

An Introduction to Clinical Lipidology

Lale Tokgözoğlu

2019 Intro to Clinical Lipidology

The approach of high – and very high risk patients in the new guidelines

Lale Tokgözoğlu

2019 ESC-EAS Dyslipidaemia Guidelines

New recommendations and concepts in the new guidelines

Alberico L. Catapano

2019 ESC-EAS Dyslipidaemia Guidelines

Management of dyslipidaemias in different clinical settings

2019 ESC-EAS Dyslipidaemia Guidelines

Important aspects related to diet and lifestyle in the new guidelines

Gabriele Riccardi

2019 ESC-EAS Dyslipidaemia Guidelines

Dyslipidaemia treatment in ACS

Lale Tokgözoğlu

2019 ESC-EAS Dyslipidaemia Guidelines

Cardiovascular risk assessment and lipid lowering for patients with DM – what do the guidelines say?

2019 ESC-EAS Dyslipidaemia Guidelines

A deep dive into EAS-ESC guidelines for dyslipidaemias

Alberico L. Catapano

ANGPTL 3 what we have learned from genetics?

88th EAS Congress 2020

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

April 13, 2021 | Consensus paper, Publications

Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe

February 16, 2021 | Consensus paper, Publications

Therapeutic Approaches – The NLA Way

Christie Ballantyne

Therapeutic Approaches – The EAS way

Alberico L. Catapano

Targets and goals – The NLA way

Carl E. Orringer

Targets and goals – The EAS way

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

February 13, 2020 | Consensus paper, Publications

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

January 9, 2020 | Consensus paper, Publications

The Clinician’s Handbook: Case-based advice for clinicians on the role of lipids and lipoproteins in atherosclerosis and cardiovascular disease

January 1, 2020 | Handbook, Publications

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

September 30, 2019 | Consensus paper, Publications

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

August 31, 2019 | Guideline, Publications

Overview of the current status of familial hypercholesterolaemia care in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

October 1, 2018 | Publications

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

April 27, 2018 | Consensus paper, Publications

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

October 16, 2017 | Publications

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

April 24, 2017 | Consensus paper, Publications

Pooling and expanding registries of familial hypercholesterolaemia toassess gaps in care and improve disease management and outcomes:Rationale and design of the global EAS Familial HypercholesterolaemiaStudies Collaboration

December 1, 2016 | Publications

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

October 27, 2016 | Consensus paper, Publications

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

April 26, 2016 | Consensus paper, Publications

Familial hypercholesterolaemia: A global call to arms

September 18, 2015 | Publications

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

May 25, 2015 | Publications

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

February 18, 2015 | Consensus paper, Publications

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

August 21, 2014 | Consensus paper, Publications

The Polygenic Nature of Hypertriglyceridaemia: Implications for Definition, Diagnosis and Management

December 23, 2013 | Consensus paper, Publications

Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease

November 23, 2013 | Consensus paper, Publications